reports
Oncocyte Reports First Quarter 2024 Financial Results
Oncocyte Reports First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission....
Oncocyte to Announce First Quarter 2024 Financial Results
Oncocyte to Announce First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the l...
Oncocyte Corporation: 2 directors
Two Directors at Oncocyte Corporation bought 37,288 shares at 2.950USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Oncocyte Reports Full Year 2023 Financial Results
Oncocyte Reports Full Year 2023 Financial Results Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP$15.8 million in gross proceeds received from private placement offering$4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectivelyGraftAssure™ transplant product launch on track for...
Oncocyte Corporation Announces $15.8 Million Private Placement of Secu...
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purcha...
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the commercialization of ...
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Resul...
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at About Oncocyte Oncocyte is a precisio...
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assay...
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays - Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte within the recent proposed rule from the FDA...
Oncocyte Reports Third Quarter 2023 Financial Results
Oncocyte Reports Third Quarter 2023 Financial Results -Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is expected beginning in 1H 2024.Significant new cl...
Oncocyte to Announce Third Quarter 2023 Financial Results
Oncocyte to Announce Third Quarter 2023 Financial Results Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day, approximately one...
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients - Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The test was able to distinguish between two preva...
Oncocyte Announces 1-For-20 Reverse Stock Split
Oncocyte Announces 1-For-20 Reverse Stock Split IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the Company’s common stock will begin to trade on a post-split basis at the market open on July 25, 2023, under the Company’s existing trading symbol “OCX”. The CUSIP number for the common stock f...
Oncocyte Begins Manufacturing Transplant Blood Test
Oncocyte Begins Manufacturing Transplant Blood Test Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. A method of checking for signs of graft damage in transplant recipients, the assay measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood. Early access for this RUO kit is expected to open in late Q4 2023. “We...
Oncocyte Reports First Quarter 2023 Financial Results
Oncocyte Reports First Quarter 2023 Financial Results Nearing Manufacturing Start Up of First Kitted Product IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023. First Quarter 2023 and Recent Highlights: Completed an equity capital raise of $13.86 million from the sale and issuance of common stock to strengthen the balance sheet and further support the Company’s product portfolio.Implemented additional cost cutting initiatives to accelerate our transition to a...
Oncocyte To Announce First Quarter 2023 Financial Results
Oncocyte To Announce First Quarter 2023 Financial Results Conference Call on Thursday, May 11 at 6:00 a.m. PT / 9:00 a.m. ET IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open. The company will host a conference call following the release at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing...
- Jonathan Moreland
HPP HUDSON PACIFIC PROPERTIES INC.
TLYS TILLYS
SFE SAFEGUARD SCIENTIFICS INC.
SFBS SERVISFIRST BANCSHARES INC
PRTK PARATEK PHARMACEUTICALS INC
KSS KOHL'S CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CEMI CHEMBIO DIAGNOSTICS INC.
AVAV AEROVIRONMENT INC.
ALOT ASTRONOVA INC.
SCWX SECUREWORKS
MRUS MERUS B V
OCX ONCOCYTE
WDFC WD-40 COMPANY
BRN BARNWELL INDUSTRIES
VBIV VBI VACCINES INC/BC
BLNK BLINK CHARGING
CSSE CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
PRPL PURPLE INNOVATION
DOMO INC.
ONCT DOMO INCORPORATED
SDC ONCTERNAL THERAPEUTICS INC
PCB SMILEDIRECTCLUB
ALTG INC.
PHAT PACIFIC CITY FINANCIAL CORP
ENX ALTA EQUIPMENT GROUP INC.
U PHATHOM PHARMACEUTICALS
INZY EATON VANCE NEW YORK MUNICIPAL BOND FUND
PUBM UNITY SOFTWARE INC.
FOA INOZYME PHARMA
RMBL PUBMATIC
AFBI FINANCE OF AMERICA COMPANIES INC.
FYBR RUMBLEON INC
ERAS AFFINITY BANCSHARES
APLD INC.
GLSI FRONTIER COMMUNICATIONS PARENT
MIRO INC.
SLG ERASCA INC
COCP APPLIED BLOCKCHAIN INC
GREENWICH LIFESCIENCES INC
MIROMATRIX MEDICAL INC
SL GREEN REALTY CORP.
COCRYSTAL PHARMA INC
Oncocyte Presents New Data at AACR
Oncocyte Presents New Data at AACR IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research. Four abstracts explore the tumor microenvironment and its potential implications for therapeutic response, leveraging expertise and technology behind DetermaIO. A fifth poster highlights exciting study results applying DetermaCNI, Oncocyte’s proprietary therapeutic monitoring blood test, to metastatic pancreatic c...
- Jonathan Moreland
TLYS TILLYS
SFE SAFEGUARD SCIENTIFICS INC.
PRTK PARATEK PHARMACEUTICALS INC
KSS KOHL'S CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CEMI CHEMBIO DIAGNOSTICS INC.
AVAV AEROVIRONMENT INC.
UHAL AMERCO
UNFI UNITED NATURAL FOODS INC.
ALOT ASTRONOVA INC.
MRUS MERUS B V
OCX ONCOCYTE
WDFC WD-40 COMPANY
BRN BARNWELL INDUSTRIES
VBIV VBI VACCINES INC/BC
BLNK BLINK CHARGING
CSSE CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
PRPL PURPLE INNOVATION
DOMO INC.
HHC DOMO INCORPORATED
SDC THE HOWARD HUGHES CORPORATION
ALIM SMILEDIRECTCLUB
PCB INC.
ALTG ALIMERA SCIENCES
PHAT PACIFIC CITY FINANCIAL CORP
ENX ALTA EQUIPMENT GROUP INC.
U PHATHOM PHARMACEUTICALS
INZY EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRAX UNITY SOFTWARE INC.
PUBM INOZYME PHARMA
FOA PRAXIS PRECISION MEDICINES
RMBL PUBMATIC
AFBI FINANCE OF AMERICA COMPANIES INC.
ERAS RUMBLEON INC
APLD AFFINITY BANCSHARES
GLSI INC.
MIRO ERASCA INC
SLG APPLIED BLOCKCHAIN INC
COCP GREENWICH LIFESCIENCES INC
MIROMATRIX MEDICAL INC
SL GREEN REALTY CORP.
COCRYSTAL PHARMA INC
Oncocyte Announces Reduction in Force
Oncocyte Announces Reduction in Force IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024. “As part of our efforts to bring our cost structure in line with our kitted product strategy and to optimize our operational efficiency, we reduced our team by approximately 20%,” said Joshua Riggs, CEO. “Those impacted have always put patients first in everything they do. We are grateful for their dedi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.